Abstract
Vical will stay alive through a reverse merger with privately held Brickell Biotech, which develops dermatology treatments. The combined company will have roughly $35 million in cash to support late-stage clinical studies of sofpironium bromide, Brickell’s anticholinergic for a form of excess sweating called axillary hyperhidrosis. In February, Vical laid off staff and said it was considering its options after ending development of its lead drug candidate, VL-2397.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
